TRANSGENE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.414 EUR | -2.88% |
|
+1.00% | +3.21% |
| Apr. 10 | Transgene: presents vaccine results at AACR | CF |
| Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.
Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology.
Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.456
EUR
Average target price
3.5
EUR
Spread / Average Target
+140.38%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.21% | 156M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.08% | 21.66B | |
| -18.35% | 20.77B | |
| -7.68% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- TNG Stock
- News Transgene
- Transgene : Gastrointestinal Cancer Drug Study Confirms Potential of Cancer-Killing Virus
